Trials / Conditions / Anal Squamous Cell Carcinoma

Anal Squamous Cell Carcinoma

18 registered clinical trials studyying Anal Squamous Cell Carcinoma — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced NCT07217171	EvolveImmune United, Inc	Phase 1
Recruiting	High Resolution Anuscopy Study NCT06697964	Universitair Ziekenhuis Brussel	—
Recruiting	MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach NCT06050707	University Health Network, Toronto	Phase 2
Recruiting	A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection NCT05328765	Latin American Cooperative Oncology Group	—
Recruiting	Adaptive Radiation in Anal Cancer NCT05838391	Columbia University	N/A
Withdrawn	Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cance NCT05582031	Translational Research in Oncology	Phase 2
Active Not Recruiting	Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer NCT04929028	National Cancer Institute (NCI)	Phase 2
Unknown	Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients NCT05374252	Sixth Affiliated Hospital, Sun Yat-sen University	Phase 3
Recruiting	Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer NCT05438836	Herlev Hospital	—
Completed	PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA P NCT05060471	Sun Yat-sen University	Phase 2
Terminated	TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy NCT04596033	Genocea Biosciences, Inc.	Phase 1
Completed	4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer NCT05130073	M.D. Anderson Cancer Center	—
Unknown	Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Local NCT02560298	ECOG-ACRIN Cancer Research Group	Phase 2
Active Not Recruiting	Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection NCT02437851	AIDS Malignancy Consortium	Phase 2
Terminated	Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays NCT02407561	Castle Biosciences Incorporated	—
Completed	Oral Rigosertib for Squamous Cell Carcinoma NCT01807546	Traws Pharma, Inc.	Phase 2
Completed	Vectibix for the Treatment of Anal Cancer NCT01285778	Grupo Espanol Multidisciplinario del Cancer Digestivo	Phase 2
Completed	A Phase 1 Study in Participants With Advanced Cancer NCT01115790	Eli Lilly and Company	Phase 1